# Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

> **NCT01253902** · PHASE4 · COMPLETED · sponsor: **Allergan** · enrollment: 164 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** bimatoprost ophthalmic solution 0.01%
- **DRUG:** travoprost ophthalmic solution 0.004%
- **DRUG:** latanoprost ophthalmic solution 0.005%

## Key facts

- **NCT ID:** NCT01253902
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2012-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01253902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01253902, "Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01253902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*